Peripheral Neuropathy Market By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

General population studies have reported that 7 to 8% of adults currently have chronic neuropathic pain, where the reported incidence is 8 cases per 1,000 individuals per year. In the U.K. alone, 26% of individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as it is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030.

Anticonvulsant Pregabalin (Lyrica, Pfizer) is among the most widely used drugs for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously reporting cost-benefit analyses to insurers and regulatory bodies. In terms of market competition, the existing brands are continually being expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion.

The report titled "Peripheral Neuropathy Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall peripheral neuropathy market, along with the market size and estimates for the duration of 2017–2025. The research study in question provides an in-depth examination of multiple market segments based on treatment type and geography.

The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies include pain relievers, anti-seizure medications, and antidepressants. Non-pharmacological therapies include transcutaneous electrical nerve stimulation, plasma exchange, intravenous immune globulin, and others (physical therapy and surgery).

Geographically, the global market for peripheral neuropathy is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global peripheral neuropathy market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global peripheral neuropathy market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global peripheral neuropathy market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Based on the type of treatment, the global market for peripheral neuropathy is segmented as follows:

  • Pharmacological Therapies
  • Pain Relievers
  • Tramadol
  • Oxycodone
  • Cyclooxygenase Inhibitors
  • Corticosteroid
  • Anti-seizure medications
  • Gabapentin
  • Pregabalin
  • Antidepressants
  • Amitriptyline
  • Doxepin
  • Nortriptyline
  • Duloxetine
  • Venlafaxine
  • Non-Pharmacological Therapies
  • Transcutaneous electrical nerve stimulation
  • Plasma exchange and intravenous immune globulin
  • Other (Physical Therapy and Surgery)

Pharmacological therapies are most commonly used and dominate the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizure medications occupied the largest share of the peripheral market at around 41% in 2016, followed by antidepressants and painkillers. Anti-seizure medications include Gabapentin and Pregabalin, which are used as the first line of treatment, with Pregabalin occupying the major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.

For the purpose of this study, the global gastrointestinal agents market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

At present, North America is observed as having the largest market for peripheral neuropathy. The rising geriatric population and growing incidences of diabetes in the region are the prime factors driving the North American peripheral neuropathy market.

The U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high numbers of research trials on peripheral neuropathy in the country, and high prices of the medication, which generated high revenue. Asia Pacific would exhibit the fastest growth rate in the global peripheral neuropathy market due to an aging population, increasing health awareness, and the high prevalence of diabetes, cancer, and HIV/AIDS.

Frequently Asked Question:

The market for Peripheral Neuropathy Market is expected to reach USD$ 1,998.8 Mn in 2025.

The Peripheral Neuropathy Market is expected to see significant CAGR growth over the coming years, at 3.2%.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Abbott Laboratories,Bristol Myers Squibb,Cipla Limited,Eli Lilly and Company. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  May 2017
Category:  Pharmaceuticals
Report ID:   58475
Report Format:   PDF
Pages:   120
Rating:    4.6 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support